Effects of Marital Status on Prognosis in Women with Infiltrating Ductal Carcinoma of the Breast: A Real-World 1: 1 Propensity-Matched Study

被引:6
|
作者
Lan, Tian [1 ]
Lu, Yunyan [2 ]
Luo, Hua [1 ]
He, Junling [1 ]
He, Jiawei [1 ]
Hu, Zujian [1 ]
Xu, Haibin [1 ]
机构
[1] Hangzhou Hosp Tradit Chinese Med, Dept Breast Surg, Hangzhou, Zhejiang, Peoples R China
[2] First Peoples Hosp Xiaoshan Dist, Dept Cardiol, Hangzhou, Zhejiang, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2020年 / 26卷
关键词
Breast Neoplasms; Marital Status; Prognosis; SEER Program; PSYCHOLOGICAL DISTRESS; CANCER; SURVIVAL; RISK; SPOUSES; HISTORY; STAGE;
D O I
10.12659/MSM.923630
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The effects of marital status on infiltrating ductal carcinoma of breast cancer (IDC) have not been studied in detail. This study investigated the impact of marital status on IDC patients. Material/Methods: SEER databases were searched from 2010 to 2015 for subjects who were married, divorced, single, and wid- owed. The influence of marital status on breast cancer-specific survival (BCSS) and overall survival (OS) of IDC patients was investigated through multivariate Cox regression analysis and Kaplan-Meier analysis. To prevent bias, propensity score matching (PSM) analysis was performed. Results: The 5-year OS was 89.6%in married patients, 84.9% in divorced patients, 83.5% in single patients, and 71.3% in widowed patients (p<0.001). The 5-year BCSS were 92.9%, 90.2%, 87.6%, and 86.4%, respectively (p<0.001). Multivariate Cox regression analysis revealed that marriage was a protective factor for patients with IDC in terms of OS (divorced: HR, 1.27; 95% CI, 1.21-1.32; p<0.001; single: HR, 1.36; 95% CI, 1.31-1.42; p<0.001; widowed: HR, 1.42; 95% CI, 1.36-1.48; p<0.001) and BCSS (divorced: HR, 1.15; 95% CI, 1.09-1.21; p<0.001; single: HR, 1.27; 95% CI, 1.21-1.33; p<0.001; widowed: HR, 1.32; 95% CI, 1.25-1.40; p<0.001). Following subgroup and PSM analysis, married patients were shown to have better OS and BCSS as opposed to divorced, single, or widowed patients. Conclusions: We identify marital status as a predictor of survival in those with IDC. Widowed patients showed the highest mortality risk.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Real-world evidence for oncological outcomes after radiotherapy or surgery for T1a-T1b glottic squamous cell carcinoma: A population-based cohort study
    Viani, Gustavo Arruda
    Moraes, Fabio Ynoe
    Marta, Gustavo Nader
    Kowalski, Luiz Paulo
    Gouveia, Andre Guimaraes
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2023, 45 (10): : 2505 - 2514
  • [22] Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1-3 positive lymph nodes: a retrospective study
    Chitapanarux, Imjai
    Tharavichitkul, Ekkasit
    Jakrabhandu, Somvilai
    Klunklin, Pitchayaponne
    Onchan, Wimrak
    Srikawin, Jirawattana
    Pukanhaphan, Nantaka
    Traisathit, Patrinee
    Vongtama, Roy
    JOURNAL OF RADIATION RESEARCH, 2014, 55 (01) : 121 - 128
  • [23] Efficacy and safety of microwave ablation for the treatment of multifocal versus unifocal T1N0M0 papillary thyroid carcinoma: a propensity-matched multicentre retrospective study
    Zhao, Zhen-Long
    Dong, Gang
    Wang, Shu-Rong
    Liu, Ying
    He, Jun-Feng
    Shi, Li-Li
    Guo, Jian-Qin
    Wang, Zhong-Hua
    Cong, Zhi-Bin
    Liu, Li-Hong
    Yang, Bei-Bei
    Qu, Chun-Ping
    Wei, Ying
    Peng, Li-Li
    Li, Yan
    Lu, Nai-Cong
    Wu, Jie
    Yu, Ming-An
    EUROPEAN RADIOLOGY, 2023, 33 (12) : 8727 - 8735
  • [24] Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer
    Lux, Michael P.
    Lewis, Katie
    Rider, Alex
    Niyazov, Alexander
    FUTURE ONCOLOGY, 2022, 18 (09) : 1089 - 1101
  • [25] Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study
    Xie, Jingyuan
    Chen, Mo
    Han, Hedong
    Xu, Ke
    Qiu, Guihuan
    Lin, Xinqing
    Song, Yong
    Ye, Jinjun
    Lv, Tangfeng
    Zhan, Ping
    THORACIC CANCER, 2023, 14 (15) : 1327 - 1338
  • [26] Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study
    Duarte, Hugo S.
    Veiga, Cassia R. P.
    Veiga, Claudimar P.
    Wainstein, Alberto J. A.
    Drummond-Lage, Ana P.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 108
  • [27] Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
    Camillo Porta
    Francesco Massari
    Tarek Taha
    Enrique Grande
    Maria T. Bourlon
    Ravindran Kanesvaran
    Umberto Basso
    Javier Molina-Cerrillo
    Teresa Alonso-Gordoa
    Zin W. Myint
    Giuseppe Fornarini
    Thomas Buttner
    Se Hoon Park
    Yüksel Ürün
    Ugo De Giorgi
    Renate Pichler
    Pasquale Rescigno
    Tomas Buchler
    Hana Studentova
    Bohuslav Melichar
    Jawaher Ansari
    Veronica Mollica
    Jakub Kucharz
    Mimma Rizzo
    Alessandro Rizzo
    Ray Manneh Kopp
    Sebastiano Buti
    Fernando Sabino Marques Monteiro
    Andrey Soares
    Aristotelis Bamias
    Matteo Santoni
    Cancer Immunology, Immunotherapy, 74 (7)
  • [28] Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
    Yu, Yi
    Wu, Tao
    Gan, Wei
    Liu, Can
    Zhang, Ran
    Zheng, Jinxiu
    Xiong, Jianping
    Chen, Jun
    Li, Junhe
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09) : 2360 - 2368
  • [29] PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study
    Gao, Loulu
    Tang, Lin
    Peng, Jieqiong
    Hu, Zixuan
    Yang, Jing
    Liu, Bo
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study
    Zhou, Yu-Wen
    Wang, Jia-Ling
    Li, Qing-Fang
    He, Yuan-Lin
    Li, Lin-Juan
    Liu, Rui-Zhi
    Chen, Ye
    Zhang, Shuang
    Qiu, Meng
    Liu, Ji-Yan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15